The closing price of Moleculin Biotech Inc. (NASDAQ: MBRX) was $1.27 for the day, down -6.62% from the previous closing price of $1.36. In other words, the price has decreased by -$0.0900 from its previous closing price. On the day, 216829 shares were traded. MBRX stock price reached its highest trading level at $1.4099 during the session, while it also had its lowest trading level at $1.2400.
Our analysis of MBRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.40 and its Current Ratio is at 8.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 21 when KLEMP WALTER V bought 22,500 shares for $1.15 per share. The transaction valued at 25,866 led to the insider holds 364,890 shares of the business.
KLEMP WALTER V bought 24,742 shares of MBRX for $25,257 on Nov 17. The CEO and President now owns 342,390 shares after completing the transaction at $1.02 per share. On Nov 16, another insider, KLEMP WALTER V, who serves as the CEO and President of the company, bought 85,213 shares for $0.97 each. As a result, the insider paid 82,614 and bolstered with 317,648 shares of the company.
Stock Price History:
Over the past 52 weeks, MBRX has reached a high of $2.33, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is 1.0588, while the 200-Day Moving Average is calculated to be 1.4306.
MBRX traded an average of 110.39K shares per day over the past three months and 106.54k shares per day over the past ten days. A total of 28.63M shares are outstanding, with a floating share count of 27.96M. Insiders hold about 0.90% of the company’s shares, while institutions hold 10.50% stake in the company. Shares short for MBRX as of Oct 13, 2022 were 57.12k with a Short Ratio of 0.05M, compared to 94.8k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.20% and a Short% of Float of 0.20%.
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.27 for the current quarter, with a high estimate of -$0.27 and a low estimate of -$0.27, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.28 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.02 and -$1.03 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$1.1, with 2 analysts recommending between -$1 and -$1.2.